Tag - PNT

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...

October 29, 2021

Executive Moves

Daniel Pearlstein joins POINT Biopharma in corporate strategy

Daniel Pearlstein was named associate director, corporate strategy, of POINT Biopharma (NASDAQ:PNT), which debuted on the Nasdaq Capital Market on July 1, 2021. Mr. Pearlstein was formerly EVP for...

September 27, 2021

Tag - PNT

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Daniel Pearlstein joins POINT Biopharma in corporate strategy

General

More